Eventide Gilead Fund Named Category King by the Wall Street Journal for the One-Year Period Ending September 28, 2012
Boston, MA, October 17, 2012 – The Eventide Gilead Fund, a mutual fund practicing values-based investing, was named as a “Category King” by the Wall Street Journal for the one-year period ending September 28, 2012. The Category King award recognizes the top 10 performing funds in each equity category for one-year performance, based on total returns. The Eventide Gilead Fund no-load shares (ticker: ETGLX) ranked #4 in the mid-cap growth equity category, out of 399 funds. During this period, the Fund generated a return of 34.45% compared with the Russell Mid-Cap Growth Index return of 26.69%, an out-performance of 7.76%.
The following table highlights the Fund’s performance over the past four years:
|
As of 9/30/2012
|
YTD return
|
1 year
return |
3 year annualized return
|
Since inception (07/08/2008) annualized return
|
| Eventide Gilead* |
13.35%
|
34.45%
|
13.40%
|
10.69%
|
| S&P 500 Total Return Index |
16.44%
|
30.20%
|
14.07%
|
5.27%
|
| Russell Mid-Cap Growth Total Return Index |
13.88%
|
26.69%
|
16.54%
|
6.29%
|
The Eventide Gilead Fund portfolio management team looks for companies they believe have both attractive returns potential, and an exemplary value creation model. Eventide lead portfolio manager Finny Kuruvilla, MD PhD particularly likes the healthcare sector in this regard: “At Eventide, we embrace both the fact that investing is ownership, as well as the role that investing plays in shaping the lives of others. We believe certain companies within Healthcare, particularly biotechnology, continue to offer investors the potential for three-fold returns: capital appreciation, pride in ownership, and a significant role in promoting human flourishing. We strive daily to afford our investors a way to achieve all three.”
The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, and based in Boston, MA.
Expenses ratios: Gross Expenses 2.58%; Net Expenses 1.68%. The advisor has agreed to maintain the Fund’s total annual operating expenses at 1.68% until at least October 31, 2012. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor’s shares, when redeemed, may be worth more or less than their original cost. Please review the fund’s prospectus for more information regarding the fund’s fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).
The S&P 500 is an index created by Standard & Poor’s Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.
Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund’s ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.
An investor should consider the Fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund’s prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836). You can also obtain a prospectus at www.eventidefunds.com. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.
Fund Contact:
Robin John
877-771-EVEN (3836), x55